Tempus AI posted Q2 results driven by growth in its oncology testing business, pushing total revenue to $382.5 million and raising 2026 revenue guidance to $1.6–$1.61 billion. The company said the momentum is tied to continuing FDA approvals for its xT CDx platform as well as review activity for its xF liquid biopsy test. Tempus also emphasized downstream strategy in minimal residual disease (MRD) through its planned acquisition of Personalis for about $1.7 billion. CEO Eric Lefkofsky framed the combined effect—xT and xF approvals plus Personalis integration—as targeting roughly $400 million of revenue uplift in 2028. The earnings update adds another layer to Tempus’s push to operationalize MRD at scale, with commercial and regulatory validation described as accelerating adoption and strengthening its portfolio beyond standalone sequencing.